The financial terms of the deal were not disclosed. Financing for the transaction was provided by European Capital.
The investment is expected to boost production, improve operations and continue research and development activities.
Euromed processes more than 4,000 tons of raw materials every year to produce approximately 600 tons of extract to serve more than 350 customers in 35 countries worldwide.
The company serves a variety of international customers and will benefit from Riverside’s global reach and resources to expand overseas, especially in the U.S. and Asia, where the dietary supplements market is expected to grow in the coming years.